Submitted by: Submitted by vasu123
Views: 10
Words: 1257
Pages: 6
Category: Business and Industry
Date Submitted: 03/29/2016 11:59 PM
Graft-versus-host Disease Market Size, Share, Global Trends, Company
Profiles, Demand, Insights, Analysis, Research, Report, Opportunities,
Segmentation and Forecast To 2023
Summary
Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem
cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the
host's cells as foreign. GVHD can progress from mild to severe forms as either acute GVHD
(aGVHD) or chronic GVHD (cGVHD). Both aGVHD and cGVHD commonly affect organs
such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes.
GlobalData epidemiologists forecast an increase in the diagnosed incident cases of aGVHD in
the 6MM, from 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed incident cases in
2023, at an Annual Growth Rate (AGR) of 4.35% during the forecast period. Similarly,
GlobalData epidemiologists forecast an increase in the diagnosed incident cases of cGVHD in
the 6MM, from 7,359 diagnosed incident cases in 2013 to 10,485 diagnosed incident cases in
2023, at an AGR of 4.25% during the forecast period.
Read Complete Report with TOC: http://www.radiantinsights.com/research/epicastreport-graft-versus-host-disease-epidemiology-forecast-to-2023
To forecast the diagnosed incident cases of aGVHD and cGVHD in the 6MM, GlobalData
epidemiologists selected nationally-representative studies that provided the diagnosed incidence
of aGVHD and cGVHD using the uniform validated diagnostic criteria and classification defined
by the Center International Blood and Marrow Transplant Research standard grading system for
aGVHD, and the standard criteria for cGVHD. In this analysis, GlobalData epidemiologists
provided detailed, clinically relevant segmentations for the diagnosed aGVHD and cGVHD
cases. Another strength of this analysis is that the same methodology was used across the 6MM,
thereby allowing for meaningful global comparisons of the diagnosed incident...